BBOT Announces New Clinical Data Advancing Its Portfolio of Three Innovative and Differentiated RAS and PI3Ka Pipeline Programs
BridgeBio Oncology Therapeutics, Inc. (BBOT)
Company Research
Source: GlobeNewswire
BBO-8520 monotherapy in patients with KRASG12C non-small cell lung cancer (NSCLC) showed a 65% objective response rate (ORR) and a 66% 6-month progression-free survival (PFS), with 83% of patients eligible for 6-month follow-up remaining on treatment for =6 months, alongside a potentially differentiated safety profile. Encouraging early efficacy signals were seen in patients with KRASG12C and STK11 and/or KEAP1 co-mutants, where all five initial patients achieved partial response.BBO-8520 in combination with pembrolizumab, at active dose levels, demonstrated promising efficacy data and a distinct, differentiated safety profile. A favorable liver safety profile was observed compared with pembrolizumab monotherapy.BBO-11818 monotherapy demonstrated a confirmed partial response (PR) in pancreatic cancer and anti-tumor activity was observed across dose levels and tumor types with tumor reductions at higher dose levels with a generally favorable, differentiated safety profile in dose escal
Show less
Read more
Impact Snapshot
Event Time:
BBOT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BBOT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BBOT alerts
High impacting BridgeBio Oncology Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
BBOT
News
- BBOT to Present at the 44th Annual J.P. Morgan Healthcare ConferenceGlobeNewswire
- BBOT Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire
- BBOT Announces Late-Breaking Preclinical Data on BBO-10203, a First-in-Class RAS:PI3Ka Breaker, at the San Antonio Breast Cancer Symposium (SABCS)GlobeNewswire
- BBOT to Participate in Upcoming December Investor Healthcare ConferencesGlobeNewswire
- BBOT Reports Third Quarter 2025 Financial Results and Update on Corporate ProgressGlobeNewswire
BBOT
Sec Filings
- 1/5/26 - Form 4
- 12/12/25 - Form 4
- 12/8/25 - Form S-1
- BBOT's page on the SEC website